Novaković, Radmila

Link to this page

Authority KeyName Variants
c79decca-56b5-43d1-b1f8-6c650e4b900d
  • Novaković, Radmila (1)
Projects
No records found.

Author's Bibliography

An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer

Rajković, Jovana; Novaković, Radmila; Grujić-Milanović, Jelica; Ydyrys, Alibek; Ablaikhanova, Nurzhanat; Calina, Daniela; Sharifi-Rad, Javad; Al-Omari, Basem

(Frontiers Media S.A., 2023)

TY  - JOUR
AU  - Rajković, Jovana
AU  - Novaković, Radmila
AU  - Grujić-Milanović, Jelica
AU  - Ydyrys, Alibek
AU  - Ablaikhanova, Nurzhanat
AU  - Calina, Daniela
AU  - Sharifi-Rad, Javad
AU  - Al-Omari, Basem
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1302
AB  - Calotropin is a pharmacologically active compound isolated from milkweed plants like Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the Asclepiadaceae family. All of these plants are recognised as medical traditional plants used in Asian countries. Calotropin is identified as a highly potent cardenolide that has a similar chemical structure to cardiac glycosides (such as digoxin and digitoxin). During the last few years, cytotoxic and antitumor effects of cardenolides glycosides have been reported more frequently. Among cardenolides, calotropin is identified as the most promising agent. In this updated and comprehensive review, we aimed to analyze and discuss the specific mechanisms and molecular targets of calotropin in cancer treatment to open new perspectives for the adjuvant treatment of different types of cancer. The effects of calotropin on cancer have been extensively studied in preclinical pharmacological studies in vitro using cancer cell lines and in vivo in experimental animal models that have targeted antitumor mechanisms and anticancer signaling pathways. The analyzed information from the specialized literature was obtained from scientific databases until December 2022, mainly from PubMed/MedLine, Google Scholar, Scopus, Web of Science, and Science Direct databases using specific MeSH search terms. The results of our analysis demonstrate that calotropin can be a potential chemotherapeutic/chemopreventive adjunctive agent in cancer pharmacotherapeutic management.
PB  - Frontiers Media S.A.
T2  - Frontiers in Pharmacology
T1  - An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer
SP  - 1160616
VL  - 14
DO  - 10.3389/fphar.2023.1160616
ER  - 
@article{
author = "Rajković, Jovana and Novaković, Radmila and Grujić-Milanović, Jelica and Ydyrys, Alibek and Ablaikhanova, Nurzhanat and Calina, Daniela and Sharifi-Rad, Javad and Al-Omari, Basem",
year = "2023",
abstract = "Calotropin is a pharmacologically active compound isolated from milkweed plants like Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the Asclepiadaceae family. All of these plants are recognised as medical traditional plants used in Asian countries. Calotropin is identified as a highly potent cardenolide that has a similar chemical structure to cardiac glycosides (such as digoxin and digitoxin). During the last few years, cytotoxic and antitumor effects of cardenolides glycosides have been reported more frequently. Among cardenolides, calotropin is identified as the most promising agent. In this updated and comprehensive review, we aimed to analyze and discuss the specific mechanisms and molecular targets of calotropin in cancer treatment to open new perspectives for the adjuvant treatment of different types of cancer. The effects of calotropin on cancer have been extensively studied in preclinical pharmacological studies in vitro using cancer cell lines and in vivo in experimental animal models that have targeted antitumor mechanisms and anticancer signaling pathways. The analyzed information from the specialized literature was obtained from scientific databases until December 2022, mainly from PubMed/MedLine, Google Scholar, Scopus, Web of Science, and Science Direct databases using specific MeSH search terms. The results of our analysis demonstrate that calotropin can be a potential chemotherapeutic/chemopreventive adjunctive agent in cancer pharmacotherapeutic management.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Pharmacology",
title = "An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer",
pages = "1160616",
volume = "14",
doi = "10.3389/fphar.2023.1160616"
}
Rajković, J., Novaković, R., Grujić-Milanović, J., Ydyrys, A., Ablaikhanova, N., Calina, D., Sharifi-Rad, J.,& Al-Omari, B.. (2023). An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. in Frontiers in Pharmacology
Frontiers Media S.A.., 14, 1160616.
https://doi.org/10.3389/fphar.2023.1160616
Rajković J, Novaković R, Grujić-Milanović J, Ydyrys A, Ablaikhanova N, Calina D, Sharifi-Rad J, Al-Omari B. An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. in Frontiers in Pharmacology. 2023;14:1160616.
doi:10.3389/fphar.2023.1160616 .
Rajković, Jovana, Novaković, Radmila, Grujić-Milanović, Jelica, Ydyrys, Alibek, Ablaikhanova, Nurzhanat, Calina, Daniela, Sharifi-Rad, Javad, Al-Omari, Basem, "An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer" in Frontiers in Pharmacology, 14 (2023):1160616,
https://doi.org/10.3389/fphar.2023.1160616 . .
1
7